Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside

Group 1 - Genmab A/S is recognized as one of the top oncology stocks to buy, with Deutsche Bank raising its price target for GMAB to DKK 2,400 from DKK 2,000 and maintaining a Buy rating, indicating strong analyst optimism regarding the company's late-stage oncology pipeline [1][3] - The company has partnered with AI research firm Anthropic to enhance its R&D capabilities through the use of agentic AI powered by Claude models, aiming for a more scalable and effective R&D process while maintaining human oversight [2] - Genmab specializes in developing innovative antibody-based therapies for cancer treatment, with its late-stage pipeline featuring promising programs such as Rina-S and Epkinly [3]